In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

State of the Art - Leucocytes and macrophages in Atherosclerosis: fuel for the fire

  • New therapy for atherosclerosis targeting folate receptor-beta expressing macrophages, presented by Y Furusho (Kagoshima, JP) - Abstract - Slides 
  • Effector memory T cells are related to the atherosclerotic process in humans and murine models, presented by E Ammirati (Milan, IT) - Abstract - Slides 
  • Essential role of CD4 T cells in Angiotensin II-induced atherosclerosis and vulnerable atherosclerotic plaque development, presented by M Pellegrin (Lausanne, CH) - Abstract - Slides 
  • MicroRNA expression in peripheral blood monocytes in different stages of atherosclerosis development in humans, presented by KL Daum (Giessen, DE) - Abstract - Slides 
  • State of the Art - Leucocytes and macrophages in Atherosclerosis: fuel for the fire, presented by P Libby (Boston, US)
Basic Sciences, Pharmacology, Genomics and Cardiovascular Pathology

White blood cells are a major component of the atherosclerotic process. Accumulating evidence for this concept was strongly supported by novel data presented in the STATE-OF-THE-ART session on Monday afternoon during the 2011 ESC congress in Paris. The session was chaired by Prof. Johannes Waltenberger from Muenster, Germany, and by Prof. Peter Libby from Boston, USA.

Specifically targeting macrophages and removing them from the atherogenic process represents a promising strategy. Dr Furusho from Japan showed data where folate receptor-beta expressing macrophages are being targeted in a mouse model of atherosclerosis, which resulted in a reduction of these cells within the atherosclerotic plaques which in turn led to reduced atherosclerotic burden of the animals. The discussion of this paper made it clear that it may be a long time before such a concept may be in clinical use; however, the initial data are encouraging.

Other immune cells of interest for the atherosclerosis field are T cells. Dr Ammirati from Milan, Italy, presented novel data on efector memory T cells in patients as well as in mice. Dr. Pellegrin from Lausanne, Switzerland, reported on his findings related to the role of CD4 T cells in atheroclerosis and their possible contribution to plaque vulnerability.

In his STATE-OF-THE-ART lecture, Prof. Peter Libby elegantly summarised the concept of immune cells in atherosclerosis by referring to the experimental milestones during the past 30 years. He also presented parts of the protocol of a clinical trial to test whether specific immune modulation may be capable of reducing the incidence of cardiovascular events in patients at risk for atherosclerosis.




State of the Art - Leucocytes and macrophages in Atherosclerosis: fuel for the fire

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.